Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Rosen Law Firm Urges Marinus Pharmaceuticals, Inc. (MRNS) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

MRNS

New York, New York--(Newsfile Corp. - June 11, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS).

Class Period: March 17, 2021 - May 7, 2024

Lead Plaintiff Deadline: August 5, 2024

If you wish to serve as lead plaintiff of the Marinus lawsuit, you can submit your contact information at https://rosenlegal.com/submit-form/?case_id=25735 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com to learn more about your rights.

According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) defendants understated the risk of failure to meet the early-stopping criteria in the RAISE trial; (2) defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial; and (3) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com, or visit our website at https://rosenlegal.com/. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/212574

Tags: